These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22846201)

  • 21. CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer.
    Liu X; Zhang X; Zhan Q; Brock MV; Herman JG; Guo M
    Cancer Biol Ther; 2012 Oct; 13(12):1152-7. PubMed ID: 22892849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon Consensus Sequence-Binding Protein 8, a Tumor Suppressor, Suppresses Tumor Growth and Invasion of Non-Small Cell Lung Cancer by Interacting with the Wnt/β-Catenin Pathway.
    Ye L; Xiang T; Zhu J; Li D; Shao Q; Peng W; Tang J; Li L; Ren G
    Cell Physiol Biochem; 2018; 51(2):961-978. PubMed ID: 30466106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of miR-194-5p inhibits cell proliferation, migration and invasion in breast cancer by regulating the Wnt/β-catenin signaling pathway.
    Yang F; Xiao Z; Zhang S
    Int J Mol Med; 2018 Dec; 42(6):3355-3363. PubMed ID: 30272253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer.
    Jia Y; Yang Y; Brock MV; Zhan Q; Herman JG; Guo M
    J Pathol; 2013 Jun; 230(2):194-204. PubMed ID: 22806826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.
    Majchrzak-Celińska A; Słocińska M; Barciszewska AM; Nowak S; Baer-Dubowska W
    J Appl Genet; 2016 May; 57(2):189-97. PubMed ID: 26337424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOX17 Antagonizes the WNT Signaling Pathway and is Epigenetically Inactivated in Clear-Cell Renal Cell Carcinoma.
    Wang L; Wang Z; Zhu Y; Tan S; Chen X; Yang X
    Onco Targets Ther; 2021; 14():3383-3394. PubMed ID: 34079284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
    Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
    Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.
    Chan DW; Mak CS; Leung TH; Chan KK; Ngan HY
    Oncotarget; 2012 Dec; 3(12):1546-56. PubMed ID: 23295859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1.
    Li W; Wu D; Niu Z; Jiang D; Ma H; He H; Zuo X; Xie X; He Y
    Int J Mol Med; 2016 Oct; 38(4):1047-54. PubMed ID: 27513557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer.
    Oishi Y; Watanabe Y; Yoshida Y; Sato Y; Hiraishi T; Oikawa R; Maehata T; Suzuki H; Toyota M; Niwa H; Suzuki M; Itoh F
    Tumour Biol; 2012 Apr; 33(2):383-93. PubMed ID: 22161215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOX17 in cellular reprogramming and cancer.
    Tan DS; Holzner M; Weng M; Srivastava Y; Jauch R
    Semin Cancer Biol; 2020 Dec; 67(Pt 1):65-73. PubMed ID: 31419525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression.
    Kuo IY; Wu CC; Chang JM; Huang YL; Lin CH; Yan JJ; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
    Int J Cancer; 2014 Aug; 135(3):563-73. PubMed ID: 24407731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CUX2/KDM5B/SOX17 Axis Affects the Occurrence and Development of Breast Cancer.
    Li L; Zhu G; Tan K; Jiang L; Li Y; Zhu X; Lin Z; Zhang X; Chen J; Ma C
    Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35881915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma.
    Li J; Ying J; Fan Y; Wu L; Ying Y; Chan AT; Srivastava G; Tao Q
    Cancer Biol Ther; 2010 Sep; 10(6):617-24. PubMed ID: 20603606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA‑21‑5p promotes epithelial to mesenchymal transition by targeting SRY‑box 17 in endometrial cancer.
    Wang C; Li Q; He Y
    Oncol Rep; 2020 Jun; 43(6):1897-1905. PubMed ID: 32236579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
    Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
    Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.
    Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC
    J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased expression of Sox7 correlates with the upregulation of the Wnt/β-catenin signaling pathway and the poor survival of gastric cancer patients.
    Cui J; Xi H; Cai A; Bian S; Wei B; Chen L
    Int J Mol Med; 2014 Jul; 34(1):197-204. PubMed ID: 24788044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.
    Merino-Azpitarte M; Lozano E; Perugorria MJ; Esparza-Baquer A; Erice O; Santos-Laso Á; O'Rourke CJ; Andersen JB; Jiménez-Agüero R; Lacasta A; D'Amato M; Briz Ó; Jalan-Sakrikar N; Huebert RC; Thelen KM; Gradilone SA; Aransay AM; Lavín JL; Fernández-Barrena MG; Matheu A; Marzioni M; Gores GJ; Bujanda L; Marin JJG; Banales JM
    J Hepatol; 2017 Jul; 67(1):72-83. PubMed ID: 28237397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.